About US
Contact us
>>Back
U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline ($GSK) and Sanofi ($SNY). But several new categories promise to break out in a big way, and we are not talking just about hepatitis C drugs. Experts suggest new classes of oncology drugs as well and cholesterol fighters will be widely used and highly priced. While a worry for payers, that is a positive for investors in companies like Merck ($MRK), Sanofi ($SNY) and Bristol-Myers Squibb ($BMY).
- Publisher：
- Publication：2015/6/29
Rare-disease specialist Alexion Pharmaceuticals ($ALXN) won a double header from the EMA today when the agency recommended approval of two of its drugs, including Kanuma, the enzyme replacement med it picked up in its $8.4 billion buyout of Synageva. It was approved to treat all ages for lethal cases of early onset lysosomal acid lipase deficiency. Alexion also won approval for Strensiq for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease, the company said. Approvals from the EMA generally come several months after a recommendation. Story | More